

Technology Advisory Committee B Interests Register

Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma [ID3760]

Publication Date: 11/01/2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Nick Latimer	Committee Member	Non-financial professional and personal	I am a member of the SchARR team for a research project investigating methods for adjusting for treatment switching in clinical trials, funded by Merck, Sharpe and Dohme. This is not drug or appraisal specific and is about developing methods. Merck, Sharpe and Dohme are the manufacturer.	24/06/22	13/07/22		It was agreed that these declarations would not prevent Professor Latimer from taking part in this discussion
		Direct Financial	In October 2021 I was paid to give Novartis staff a training session on survival analysis. This was not product or appraisal specific and was about methods (Novartis are listed as a comparator company.)				

Ms Sophie-Ann Scott	Patient expert	Indirect financial	My organisation - Kidney cancer UK - has received funding from Pfizer Merck and BMS for various projects.	14/09/21	13/07/22		It was agreed that this declaration would not prevent Sophie-Ann Scott from providing expert advice during this discussion.
Professor Thomas Powles	Clinical expert	Direct financial interest	I have received remuneration by MSD for my work on advisory boards	12/05/22	13/07/22		It was agreed that these declarations would not prevent Professor Powles from providing expert advice during this discussion.
		Indirect financial interest	I have sat on advisory/research boards (honorary) for the following pharmaceutical companies: AstraZeneca, BMS, Exelixis, Incyte, Ipsen, Merck, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, and Roche. I received travel/accommodation expenses from the following pharmaceutical companies: Roche, Pfizer, MSD, AstraZeneca, Ipsen, and my institution has received grants/funding from AstraZeneca, Roche, BMS, Exelixis, Ipsen, Merck, MSD,	27/09/21			

			Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai.				
Dr Ricky Frazer	Clinical Expert	Indirect Financial	I have been paid for speaking or advisory from Bristol-Myers Squibb Pharmaceuticals (nivolumab, ipilimumab) Eusa Pharma UK (tivozanib) Ipsen (cabozantinib) Novartis (pazopanib) & Pfizer (sunitinib) MSD (Pembrolizumab), Eisai (Lenvatinib) and Merck-Pfizer Alliance (Avelumab and Axitinib) It was agreed that this declaration would not prevent Dr Frazer from providing expert advice during this discussion.	21/09/21	13/07/22		It was agreed that this declaration would not prevent Dr Frazer from providing expert advice during this discussion.
Paula Brown	Patient Expert	Indirect Financial	I worked for Sanofi Pasteur MSD for 11 years and left in 2008. The company was a 50/50 joint venture between Sanofi and MSD's vaccine division. I have no ongoing relationship with MSD and	08/06/22	13/07/22		It was agreed that this declaration would not prevent Paula Brown from providing expert advice during this discussion

			have never been directly employed by them.				
--	--	--	---	--	--	--	--